P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy
Woodard G, Wang S, Kratz J, Haro G, Gubens M, Blakely C, Jahan T, Jones K, Mann M, Jablons D. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy. Journal Of Thoracic Oncology 2018, 13: s835. DOI: 10.1016/j.jtho.2018.08.1487.Peer-Reviewed Original ResearchLung adenocarcinoma patientsAdjuvant chemotherapyStage IAAdenocarcinoma patientsChemotherapyPatients